Cody, the FDA response to our Pre IND application.
Post# of 36533
(Total Views: 273)
Posted On: 08/24/2020 11:42:21 AM
Cody, the FDA response to our Pre IND application.
"The Ii-Key-SARS-CoV-2 is designed as a “Complete Vaccine” that has the potential to induce the
T-Cell and antibody immune responses that can provide protective immunity with long-lasting
immunologic memory against SARS-CoV-2 in a highly specific manner to ensure safety. With their
response, the FDA will comment on the Phase I/II clinical trial plan and will provide guidance on
the overall development program for the Ii-Key-SARS-CoV-2 vaccine."
https://storage.googleapis.com/wzukusers/user...7_2020.pdf
"The Ii-Key-SARS-CoV-2 is designed as a “Complete Vaccine” that has the potential to induce the
T-Cell and antibody immune responses that can provide protective immunity with long-lasting
immunologic memory against SARS-CoV-2 in a highly specific manner to ensure safety. With their
response, the FDA will comment on the Phase I/II clinical trial plan and will provide guidance on
the overall development program for the Ii-Key-SARS-CoV-2 vaccine."
https://storage.googleapis.com/wzukusers/user...7_2020.pdf
(1)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Disclaimer: Of course, all of this is my opinion and you should not make any investment decisions based on my opinion. I have not received any non-public information.
Scroll down for more posts ▼